VHL and renal cell carcinoma: To evaluate the relevance of Vhl gene loss in ICB therapy, we conducted anti-programmed death 1 (αPD1) therapy in several Vhl-deficient tumor lines following the schedule depicted in Figure S1D. In the murine RCC Renca tumor model, VHL loss alone suppressed tumor growth (Figures S1A and 1A).